Coagulation factors in renal adenocarcinoma.
Coagulation factors, including plasma fibrinogen, serum fibrinogen-fibrin degradation products, platelet counts and prothrombin times, were studied in patients with renal adenocarcinoma. Plasma fibrinogen levels were elevated and correlated with tumor stage, disease activity and therapy. Fibrinogen-fibrin degradation product levels also were elevated, although such elevations did not correlate with other parameters. Platelet count and prothrombin times were normal. Fibrinogen may be a valuable marker of disease activity in patients with renal carcinoma. In addition, since significant intratumoral fibrin deposits have been demonstrated anticoagulants or fibrinolytic agents may enhance cytotoxic therapy and should be considered in adjunctive chemotherapeutic protocols.
D000230:Adenocarcinoma / Q000097:blood* / Q000601:surgery; D001779:Blood Coagulation Factors / Q000032:analysis; D001780:Blood Coagulation Tests; D001800:Blood Specimen Collection; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D011517:Prothrombin Time
D001779:Blood Coagulation Factors; D005338:Fibrin Fibrinogen Degradation Products; D005340:Fibrinogen